HARBOR study shows similar results for four anti-VEGF dosing regimens

BALTIMORE — Four dosing regimens of ranibizumab yielded similar safety and efficacy, with few ocular and systemic adverse events, a speaker said here.“This is significant and clinically meaningful in terms of performance of treatment within all four arms,” Carl D. Regillo, MD, OSN Retina/Vitreous Board Member, said at Macula 2013.

Full Story →